Format

Send to

Choose Destination
See comment in PubMed Commons below
CNS Drugs. 2013 Aug;27(8):591-609. doi: 10.1007/s40263-013-0080-z.

Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Author information

1
Department of Neurology, Johns Hopkins University, Baltimore, MD, USA. jioh@jhsph.edu

Abstract

Treatment options for relapsing-remitting multiple sclerosis (RRMS) have been continuously expanding in recent years, and the emergence of a number of oral disease-modifying agents (DMAs) has significantly changed the landscape of therapeutic options for MS patients. Many of these oral DMAs have demonstrated satisfactory safety and tolerability profiles in clinical trial settings, but the long-term safety of these agents is an important concern. This review discusses salient points on the safety and clinical efficacy of the approved and emerging novel oral therapies in RRMS, including fingolimod, teriflunomide, dimethyl fumarate, laquinimod, and cladribine.

PMID:
23801528
DOI:
10.1007/s40263-013-0080-z
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center